Novartis | NVS - Capital Social e Reservas





Capital Social e Reservas Alterar Data
AbbVie USD -6.66B 3.39B 2026-03
Amgen USD 9.19B 532M 2026-03
AstraZeneca USD 47.33B 1.33B 2026-03
Bausch Health Companies USD -2.06B 1.5B 2026-03
Biogen USD 18.65B 394.9M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Canopy Growth CAD 697.59M 60.58M 2026-03
Corcept Therapeutics USD 637.99M 9.82M 2026-03
Drreddys Laboratories INR 380.46B 376.31B 2026-03
Eli Lilly USD 31.2B 4.66B 2026-03
Gilead Sciences USD 23.52B 897M 2026-03
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
Glaxosmithkline GBP 17.42B 4.64B 2026-03
J&J USD 81.19B 358M 2026-03
Merck USD 45.88B 6.73B 2026-03
Novartis USD 38.93B 7.2B 2026-03
Novartis USD 38.93B 7.2B 2026-03
Pacira USD 653.89M 39.22M 2026-03
Perrigo USD 2.5B 436.7M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Phibro Animal Health USD 361.83M 29.47M 2026-03
Prestige Brands USD 1.89B 58.06M 2026-03
Roche Holding CHF 33.8B 758M 2025-12
Sanofi EUR 72.81B 1.1B 2026-03
Sanofi EUR 73.14B 1.43B 2026-03
Supernus Pharmaceuticals USD 1.08B 15.09M 2026-03
Zoetis USD 3.23B 98M 2026-03